U.S. pharma giant copyright scrapped two experimental weight loss tablets last year—a after-each day capsule, lotiglipron, on account of elevated liver enzymes and also a twice-daily tablet, danuglipron, as a result of robust Unwanted side effects—but CEO Albert Bourla has stated the